Somatropin + Somatropin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency
Trial Timeline
Jun 1, 1997 → Dec 1, 1998
NCT ID
NCT00570011About Somatropin + Somatropin
Somatropin + Somatropin is a phase 3 stage product being developed by Eli Lilly for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00570011. Target conditions include Growth Hormone Deficiency.
What happened to similar drugs?
11 of 20 similar drugs in Growth Hormone Deficiency were approved
Approved (11) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191165 | Phase 3 | Completed |
| NCT00570011 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency